In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible.

Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.

Background: Dengue, the fastest-spreading vector-borne disease (VBD), significantly burdens global health systems. This study analyzed the trends in the global burden of dengue from 1990 to 2021, utilizing data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021). Methodology/Principal findings: We retrieved data from GBD 2021 regarding dengue, including the number of incidences and age-standardized incidence rate (ASIR), the number of deaths and age-standardized death rate (ASDR), disability-adjusted life-years (DALYs) and age-standardized DALYs. The estimated annual percentage change (EAPC) of ASIR, ASDR, and standardized DALYs rate was calculated to quantify trends over time. In addition, the correlations between dengue burden and sea level rise, as well as the Socio-Demographic Index (SDI), were evaluated. In this study, it was observed that from 1990 to 2021, the global incidence of dengue escalated from 26.45 million to 58.96 million cases, accompanied by an increase in related deaths from 14,315 to 29,075, and DALYs rising from 1.25 million to 2.08 million years. These data collectively indicate that the disease burden approximately doubled, with South Asia, Southeast Asia, and tropical Latin America being the most severely affected regions. The disease burden remained substantial in middle and low-middle-SDI regions, whereas high-middle and high SDI regions experienced pronounced growth rates in ASIR, ASDR, and age-standardized DALYs rate. Adolescents and the elderly showed higher incidence, yet children under 5 had the highest DALYs. Correlation analyses revealed an inverted U-shaped relationship between the SDI and both the ASDR and age-standardized DALYs rate, and changes in sea level height strongly correlated with the overall dengue burden. Conclusions/Significance: The global dengue burden has surged due to climate change, vector transmission, and population mobility. Increased focus and tailored control strategies are essential, particularly in South Asia, Southeast Asia, and Latin America.

Mosquito-borne diseases are major global health problems that threaten nearly half of the world’s population. Conflicting resources and infrastructure required by the coronavirus disease 2019 (COVID-19) global pandemic have resulted in the vector control process being more demanding than ever. Although novel vector control paradigms may have been more applicable and efficacious in these challenging settings, there were virtually no reports of novel strategies being developed or implemented during COVID-19 pandemic. Evidence shows that the COVID-19 pandemic has dramatically impacted the implementation of conventional mosquito vector measures. Varying degrees of disruptions in malaria control and insecticide-treated nets (ITNs) and indoor residual spray (IRS) distributions worldwide from 2020 to 2021 were reported. Control measures such as mosquito net distribution and community education were significantly reduced in sub-Saharan countries. The COVID-19 pandemic has provided an opportunity for innovative vector control technologies currently being developed. Releasing sterile or lethal gene-carrying male mosquitoes and novel biopesticides may have advantages that are not matched by traditional vector measures in the current context. Here, we review the effects of COVID-19 pandemic on current vector control measures from 2020 to 2021 and discuss the future direction of vector control, taking into account probable evolving conditions of the COVID-19 pandemic.

Metarhizium anisopliae (Hypocreales: Clavicipitaceae, M. anisopliae), as an invertebrate fungal pathogen, has played a significant role in the control of many agricultural pests and human disease vectors. M. anisopliae is typically used as a chemical in dry or liquid formulations of large numbers of aerial conidia. The conidia can directly infect arthropod pests by penetrating their cuticular layer. The availability of the complete genome of M. anisopliae and capable techniques for its transformation have brought several developments in its use as a pest controller. For prospects, more in-depth research to improve fermentation and formulation technologies is needed, while multistress-tolerant and engineering entomopathogenic strains are selected to promote the widespread acceptance and usefulness of M. anisopliae as a cost-effective fungal biopesticide. Here, we provide an overview of the pathogenesis and formulation strategies, as well as the host ranges and molecular approaches of increasing virulence and efficacy. Several studies of this fungus pathogen demonstrated that M. anisopliae can be an efficient biocontrol agent and has great potential for further research and development.

Background: Dengue fever (DF) and West Nile fever (WNF) have become endemic worldwide in the last two decades. Studies suggest that individuals with diabetes mellitus (DM) are at a higher risk of developing severe complications from these diseases. Identifying the factors associated with a severe clinical presentation is crucial, as prompt treatment is essential to prevent complications and fatalities. This article aims to summarize and assess the published evidence regarding the link between DM and the risk of severe clinical manifestations in cases of DF and WNF. Methodology/Principal findings: A systematic search was conducted using the PubMed and Web of Science databases. 27 studies (19 on DF, 8 on WNF) involving 342,873 laboratory-confirmed patients were included in the analysis. The analysis showed that a diagnosis of DM was associated with an increased risk for severe clinical presentations of both DF (OR 3.39; 95% CI: 2.46, 4.68) and WNF (OR 2.89; 95% CI: 1.89, 4.41). DM also significantly increased the risk of death from both diseases (DF: OR 1.95; 95% CI: 1.09, 3.52; WNF: OR 1.74; 95% CI: 1.40, 2.17). Conclusions/Significance: This study provides strong evidence supporting the association between DM and an increased risk of severe clinical manifestations in cases of DF and WNF. Diabetic individuals in DF or WNF endemic areas should be closely monitored when presenting with febrile symptoms due to their higher susceptibility to severe disease. Early detection and appropriate management strategies are crucial in reducing the morbidity and mortality rates associated with DF and WNF in diabetic patients. Tailored care and targeted public health interventions are needed to address this at-risk population. Further research is required to understand the underlying mechanisms and develop effective preventive and therapeutic approaches.